IP Library › Granted Patent US 11,884,695
Granted Patent B2
US 11,884,695 · App. 18/045,596 · Granted Jan 30, 2024

Heavy vitamin B12 derivatives

Inventor: Peter Anderson (Orange, AU)
Assignee: CHARLES STURT UNIVERSITY
C07H23/00G01N30/7233G01N33/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,884,695
App. No.
18/045,596
Granted
Jan 30, 2024
Kind
B2
Abstract

The invention discussed in this application relates to vitamin B12-based compounds that are useful as quantitative standards, particularly for the assessment of vitamin B12 deficiency.

Claims (25)

1. A heavy vitamin B12 having a mass shift of at least +8 over unlabelled vitamin B12, wherein the heavy vitamin B12 comprises eight or nine 13 C atoms and the eight or nine 13 C atoms are located in the dimethylbenzimidazole moiety of the vitamin.

2. The heavy vitamin B12 of claim 1 , comprising eight 13 C atoms.

3. The heavy vitamin B12 of claim 1 , comprising nine 13 C atoms.

4. The heavy vitamin B12 of claim 1 , wherein the heavy vitamin B12 has a mass shift of from +8 to +11 over unlabelled vitamin B12.

5. The heavy vitamin B12 of claim 4 , wherein the heavy vitamin B12 has a mass shift of +8 over unlabelled vitamin B12.

6. The heavy vitamin B12 of claim 4 , wherein the heavy vitamin B12 has a mass shift of +9 over unlabelled vitamin B12.

7. The heavy vitamin B12 of claim 4 , wherein the heavy vitamin B12 has a mass shift of +10 over unlabelled vitamin B12.

8. The heavy vitamin B12 of claim 4 , wherein the heavy vitamin B12 has a mass shift of +11 over unlabelled vitamin B12.

9. The heavy vitamin B12 of claim 1 , wherein the heavy vitamin B12 is a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof:

wherein

R is 5′-deoxyadenosyl, OH, H 2 O, CH 3 , or CN.

10. The heavy vitamin B12 of claim 9 , wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloric, phosphoric, hydrobromic, malic, glycolic, fumaric, sulfuric, sulfamic, sulfanilic, formic, toluenesulfonic, methanesulfonic, benzenesulfonic, ethane disulfonic, 2-hydroxyethylsulfonic, nitric, benzoic, 2-acetoxybenzoic, citric, tartaric, lactic, stearic, salicylic, glutamic, ascorbic, pamoic, succinic, fumaric, maleic, propionic, hydroxymaieic, hydroiodic, phenylacetic, alkanoic, sodium, potassium, calcium, aluminum, lithium, and ammonium salts.

11. The heavy vitamin B12 of claim 1 , wherein the heavy vitamin B12 further comprises one or more 2 H atoms.

12. The heavy vitamin B12 of claim 11 , wherein the heavy vitamin B12 further comprises two 2 H atoms.

13. The heavy vitamin B12 of claim 11 , wherein the one or more 2 H atoms are also located in the dimethylbenzimidazole moiety of the vitamin.

14. The heavy vitamin B12 of claim 1 , wherein at least 90% of the molecules in the heavy vitamin B12 have a single mass shift.

15. The heavy vitamin B12 of claim 14 , wherein at least 95% of the molecules in the heavy vitamin B12 have a single mass shift.

16. A pharmaceutical composition comprising the heavy vitamin B12 of claim 1 , and one or more pharmaceutically acceptable carrier substances, diluents or excipients.

17. A method of assessing a patient for vitamin B12 deficiency, the method comprising:

administering to a patient an effective amount of the heavy vitamin B12 of claim 1 , or a pharmaceutical composition thereof,

obtaining a biological fluid sample from the patient, and

analysing the sample to determine the quantity of the heavy vitamin B12 in the sample.

18. The method of claim 17 , wherein the biological fluid sample is a blood sample.

19. The method of claim 18 , wherein the red blood cells are separated from the serum.

20. The method of claim 17 , wherein the heavy vitamin B12 is administered parenterally or orally.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2023
From: ANDERSON, PETER
To: CHARLES STURT UNIVERSITY
Reel/Frame 064987/0316 →
Continuity (3)
Continuation 17128511 · Dec 21, 2020
Continuation 15546628
Related Publication 20230183287A1 · Jun 15, 2023